trending Market Intelligence /marketintelligence/en/news-insights/trending/jp0k0xcpjsfhrduvnglszq2 content esgSubNav
In This List

Dimerix raises A$7.6M via oversubscribed entitlement offer

Blog

Insight Weekly: US stock performance; banks' M&A risk; COVID-19 vaccine makers' earnings

Blog

Global M&A By the Numbers: Q3 2021

Blog

Post-webinar Q&A: Global Credit Risk Trends 2021 and Beyond

Blog

University Essentials: From Crisis to Resilience – Navigating Sustainable Recovery


Dimerix raises A$7.6M via oversubscribed entitlement offer

Dimerix Ltd. raised about A$7.6 million through a previously announced 1-for-2 entitlement offer of ordinary shares.

The Melbourne, Australia-based company issued about A$3.1 million of new shares priced at 12 Australian cents each under the offer, and received about A$4.5 million in additional funding through its oversubscribed shortfall.

Dimerix will use proceeds to take its lead compound DMX-200 into a phase 2 kidney disease trial and help develop commercial scale batches for the drug. Funds will also support preparations for DMX-200's phase 3 evaluation, along with other pipeline opportunities.